Overview

Subacute Effect of Tolvaptan on Total Kidney Volume in Adult Patients With Autosomal Dominant Polycystic Kidney Disease

Status:
Unknown status

Trial end date:
2020-04-01

Target enrollment:

Participant gender:

Summary

Investigator initiated controlled multi-centre trial in a Prospective, Randomised, Open, Blinded Endpoint (PROBE) design. Patients will be randomised in a 1:1 ratio either to treatment with tolvaptan for six weeks followed by six weeks observation without trial medication or no tolvaptan treatment, but following the same visit and investigation plan as the subjects taking tolvaptan.

Phase:

Phase 4

Details

Lead Sponsor:

Lisbet Brandi

Treatments:

Tolvaptan